Hassle-free Antibody Discovery

About Us

Experienced. Fast. Affordable.

At Immunovive, we strive to make a difference in the world of immunotherapeutics. Our mission is to accelerate life science research and biologics discovery by providing a high-quality antibody discovery service rapidly and affordably. Our BinderGenᵀᴹ lead discovery platform generates diverse in vivo-derived monoclonal antibody binders in 6 weeks designed to empower downstream drug development applications including target validation, proof-of-concept, lead optimization, and multimodality engineering. The Immunovive team brings decades of expertise, innovation, and leadership that has delivered success to thousands of biotherapeutic investigators worldwide. As a strictly fee-for-service preclinical CRO committed to mobilizing therapeutic ideas to proof-of-concept all rights to the resultant antibodies are 100% retained by the client.

Our Team

Devin E. Turner, Ph.D., Founder and CEO

Devin Turner has over 15 years of successful leadership in antibody discovery companies. Most recently, Devin was the Head of Antibody Discovery Services at Alloy Therapeutics where he led a world-class multidisciplinary team delivering fully human antibody-based therapeutic leads from Alloy’s state-of-the-art suite of humanized mice. Prior to Alloy Devin founded Abveris, a biotech company based on a unique technology Devin had created to address unmet needs in biotherapeutics research. In six years, Devin led Abveris through substantial growth, technological creation, and a successful exit while delivering scores of IND-enabling therapeutic lead molecules to a broad range of human diseases. Devin continues his passion for immunotherapeutics through his latest company, Immunovive, which accelerates biologics discovery and research by providing access to a robust in vivo-based hit generation platform free of IP encumbrances. Devin earned his B.S. in Molecular, Cellular, and Developmental Biology from UCLA and his Ph.D. in Immunology from Harvard Medical School.

Craig Bencsics, Ph.D., Head of In Vivo Antibody Discovery 

For over 25 years Craig has acquired expertise in many facets of antibody discovery ranging molecular biology, protein engineering, assay development and high throughput screening. At Tectonic Therapeutic, Craig managed a cross-functional team to isolate monoclonal antibodies via HTP hybridoma generation and single B cell isolation. As Lead Scientist at the Dana Farber Cancer Institute Monoclonal Antibody Core Craig consulted, designed, and executed hundreds of antibody discovery campaigns ranging many therapeutic areas and led the development of HTP variable region cloning and recombinant protein engineering. Working directly with the President and CSO Craig helped develop the scientific strategy at GO Therapeutics, created anti-glycopeptide antibodies, and created a multitude of critical reagents using CRISPR protocols. At Immunovive, Craig applies decades of expertise to design optimized workflows that rapidly deliver customized biotherapeutic molecules to clients. In his free time, you can find Craig spending time with his wife and daughter, watching movies (especially Chicago-based or sports movies), following Chicago and Boston sports teams, and listening to jazz and early R&B/soul music.